Navigation Links
Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
Date:9/10/2007

BARCELONA, Spain, Sept. 10 /PRNewswire/ -- Elekta today unveiled a new member of the Elekta family of linear accelerators at the European Society of Therapeutic Radiation Oncologists (ESTRO) 2007 meeting. At an 11 a.m. unveiling ceremony in the Elekta booth, Elekta President and CEO Tomas Puusepp announced the launch of Elekta Compact(TM), a new addition to Elekta's product line of linear accelerators that offers an easy to implement, more affordable solution for radiation therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )

Elekta Compact purposefully was designed with a single low-energy photon beam and a small footprint specifically, so it is ideally positioned for use in a small treatment room and in specialized markets. Its efficient design makes it more accessible to a wider range of health care providers who want to give their patients the optimal care in radiation therapy. "Elekta is committed to fighting cancer and enhancing patients' quality of life," says Puusepp. "With the addition of Elekta Compact to our product portfolio, Elekta is now a provider of linear accelerators across the full spectrum of price and performance specifications."

Smaller footprint targets untapped markets

In rooms that previously contained a Cobalt unit, or a treatment room with limited space, Elekta Compact may be an appropriate first step. "For former Cobalt users who want a simple linear accelerator that is a 'workhorse' in providing cancer treatment with fewer complications, Elekta Compact can fill a treatment room that might otherwise lay empty," says Olof Sanden, Executive Vice President, Elekta, Europe.

Elekta Compact was designed and positioned to give all customers access to this exceptional product. "We haven't forgotten that there's a need for appropriate products to meet all customers' needs," says Russ Cox, Manager of Oncology
'/>"/>

SOURCE Elekta, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. TeraMedica launches information manager
7. GE Healthcare launches hybrid electronic record
8. Cedara launches new version of DICOM toolkit
9. Merge launches Spanish version of imaging tool
10. Doyle launches 2025 alternative energy plan
11. Jellyfish launches comparative shopping website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies ... company developing first in class collagenase-based products marketed ... CCH) in the U.S. and XIAPEX ® ... results from a randomized, double-blind Phase 2a study ... or edematous fibrosclerotic panniculopathy. The results showed that ...
(Date:8/21/2014)... , August 21, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... hormone therapy, is a means of replacing ... by the body. This type of therapy ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 Mathematic studies ... Harvard University , and funded by the Jeffrey ... cells within tumors can be visually identified for elimination. These ... growth. The study, which shows a topological map of what ... time in cancer research, for while tumor cells can be ...
(Date:8/21/2014)... August 21, 2014 Ontotext S4 ... by Ontotext . Now the same enterprise ... of structured and unstructured data is available to start-ups ... of enterprise technology. Organizations that do not have resources ... management can use S4 since there is no need ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
... ... , ... (Vocus) February 4, 2010 -- Qteros, Inc. , a leading developer of second-generation ... announced today that Mick Sawka has joined the company as Vice President, Business Development, ...
... PARK, N.C. , Feb. 4 ... antiviral therapeutics, announced today that Gwendolyn Powell Painter , ...   , Dr. Painter has more than 20 years of ... clinical safety and pharmacovigilance, and occupational and environmental medicine.  In ...
... Mass. , Feb. 4 Interleukin Genetics, Inc. (NYSE Amex: ... at the 2010 BIO CEO & Investor Conference. The 12th Annual BIO ... the Waldorf-Astoria in New York . , Interleukin Genetics Chief Executive ... Company and discuss recent milestones at 1:00 p.m. ET in ...
Cached Biology Technology:Biofuels Technology Leader Qteros Names Mick Sawka Vice President, Business Development 2Biofuels Technology Leader Qteros Names Mick Sawka Vice President, Business Development 3Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer 2Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer 3Interleukin Genetics to Present at the 12th Annual BIO CEO Conference 2
(Date:8/22/2014)... (Edmonton) Thanks to important discoveries in basic and ... cancer has mobilized into a complex offensive spanning ... of Alberta chemistry lab could help find new ... developed a compound that targets a specific enzyme ... activity in cells from brain tumours. , Chemistry ...
(Date:8/22/2014)... is a multifunctional enzyme that localizes ... neuroprotective and cholesterol-synthesizing activities. DHCR24 overexpression ... amyloid β deposition. Dr. Xiuli Lu ... China constructed two recombinant adenoviruses (Ad-rSYN1-DHCR24-myc ... specifically in neuronal cells. They also ...
(Date:8/21/2014)... a significant reduction in smog-producing toxins in past ... A new study shows that while the Greater ... the toxins that contribute to smog, the city ... air pollution., Smog, which can cause or aggravate ... bronchitis, is produced by a set of complex ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2
... largest study of migraines, researchers have found 5 genetic regions ... onset of migraine. This study opens new doors to understanding ... The team identified 12 genetic regions associated with migraine susceptibility. ... known to play a role in controlling brain circuitries and ...
... study shows that the predator-prey relationship can affect the ... influence on the environment may offer a new way ... climate change. The study, conducted by researchers ... comes out this week in the Proceedings of ...
... - 250 million years ago, a mammal forerunner and ... Africa, Australia and France have discovered a world first ... burrow from the Karoo Basin of South Africa. ... and fossilized after being trapped by a flash flood ...
Cached Biology News:Getting to grips with migraine 2New study shows predators affect the carbon cycle 2Oddest couple ever found 2Oddest couple ever found 3Oddest couple ever found 4
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Biology Products: